Good morning and welcome to the AdvanSix Third Quarter 2017 Earnings conference call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today’s presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on your touchtone phone. To withdraw your question, please press star then two. Please note this event is being recorded. I would now like to turn the conference over to Adam Kressel, Director of Investor Relations. Please go ahead, sir.

Thank you, Rachel. Good morning and welcome to AdvanSix’s third quarter 2017 earnings conference call. With me here today are President and CEO, Erin Kane, and Senior Vice President and CFO, Michael Preston. This call and webcast, including any non-GAAP reconciliations, are available on our website at investors.advansix.com. Note that elements of this presentation contain forward-looking statements that are based on our best view of the world and of our business as we see it today. Those elements can change and the actual results could differ materially from those projected, and we ask that you consider them in that light. We refer you to the forward-looking statements included in our press release and earnings presentation. In addition, we identify the principle risks and uncertainties that affect our performance in our SEC filings, including our annual report on Form 10-K. This morning, we’ll review our financial results for the third quarter 2017 and share with you our outlook for our key product lines and end markets. Finally, we’ll leave time for your questions at the end. With that, I’ll turn the call over to AdvanSix’s President and CEO, Erin Kane.

Thanks Adam, and good morning everyone. Thank you for joining us and for your continued interest in AdvanSix. As you saw in our press release, AdvanSix delivered another strong quarter highlighted by higher sales volume, margin expansion, and improved cash flow generation. Mike will detail the full results in a moment, though I’d like to highlight the following. Sales for the quarter were $367 million with both higher volume and pricing contributing to the improvement year over year. We generated over $50 million of EBITDA in the quarter, a significant increase from the prior year, and expanded margins by 190 basis points. These improved results were inclusive of a $4.4 million unfavorable LIFO reserve adjustment. Lastly, our cash flow generation continued to improve with roughly $18 million of free cash flow in the quarter. Our end markets remain dynamic, but we’re seeing more favorable conditions overall. Nylon and intermediates pricing has been supported through 2017 by a tightened supply and demand environment as well as higher raw material costs, while ammonium sulfate fertilizer prices modestly firmed late in the quarter with the uptick in overall nitrogen pricing. The hurricanes in the U.S., particularly Harvey in Q3 had varying impacts across our supply chain. Overall, when you consider the puts and takes from raw material timing and logistics, fixed cost absorption and commercial pricing, the net impact on our second half results is minimal. From an operations perspective, our manufacturing plants continue to run at relatively high utilization rates given our mid-Atlantic locations and that we had the right size supply chain buffers in place ahead of the hurricane season. Tightened supply conditions support improvements in pricing for some of our key product lines, however it is also important to note that operations for certain downstream customers were also impacted by…

Thanks Erin and good morning everyone. I’m now on Slide 4, where I’ll cover the third quarter financial results. As Erin indicated, we’ve continued the momentum seen in the first half. Sales in the quarter came in at $367 million, and that’s up 13% compared to last year. Volume was up 5% with continued high operating rates at our manufacturing sites. Pricing also contributed to the top line, increasing 8% overall, and that included a 4% favorable impact from the market based pricing and a 4% benefit from the pass through of higher raw material costs. We saw favorable industry supply and demand conditions in our nylon and caprolactam product lines partially offset by a decline in ammonium sulfate pricing. As for raw material pass through pricing, we’ve seen that impact moderate throughout 2017 but remain higher on a year-over-year basis. As a reminder, prices for our end products typically track a spread over the underlying raw material costs which are largely sensitive to changes in oil prices. With these inputs increasing year over year trending with underlying oil prices, our sales in the third quarter also grew. EBITDA of $50 million in the quarter increased 32% versus prior year driven primarily by higher sales volume and the favorable impact of market-based pricing. EBITDA margin also expanded year over year, up 190 basis points to 13.7%. These results included a non-cash $4.4 million unfavorable pre-tax income impact from a LIFO inventory reserve adjustment due to a reduction in inventories since 2016 year-end primarily associated with overall lower raw material levels. Taking the LIFO inventory adjustment into consideration, EBITDA and margins would have increased even more significantly year over year. Items below EBITDA were also as expected. Depreciation increased by about $2.3 million compared to last year, driven by our broad scope of capital investments as we’ve discussed before, while interest expense increased by about $2 million. Our diluted share count for the quarter was approximately 31.2 million shares, and as we shared before, basic and diluted EPS for all periods prior to the spinoff reflect the number of shares that were distributed as of the spin, which is approximately 30.5 million shares. Earnings per share reached $0.68 in the quarter compared to $0.54 in the prior year period - that’s up 26% on a year-over-year basis. Finally, we generated approximately $18 million of free cash flow in the quarter, up over $11 million from the prior year period, and that was primarily driven by higher net income and deferred taxes partially offset by pension contributions and a slight increase in capex. Overall, cash flow generation is improving and we continue to manage working capital levels efficiently. Let me turn the call back to Erin to discuss what we’re seeing in each of our product lines.

Thanks Mike. I’m now on Slide 5 to discuss our nylon product line, which includes our caprolactam resin and films products and represented over 45% of our sales in the quarter. Similar to last quarter, the chart on the right side of the page depicts the Asia benzene to caprolactam spreads and caprolactam to resin spreads, with the caprolactam price reflecting the Asia import contract in Taiwan and South Korea. In addition, we’ve shown the global composite index again which encompasses benzene to caprolactam spreads across four regions: the U.S., Europe, China, and Rest of Asia. It provides a weighted average view based on each region’s percentage of global caprolactam demand. We’ve seen generally balanced to tighter supply conditions across North America and Europe while China’s structural imbalances continue to create volatility. In China, while reported caprolactam capacity has come online, government imposed environmental policies appear to be more systematic which has resulted in lower utilization, increased cost and approvals to start-up capacity or restart production after a turnaround. Availability of key feedstock materials, notably cyclohexanone, are also impacted as a result of these constraints. With the volatility in supply and demand fundamentals in the region, we continue to see significant moves in China pricing and spreads. Given these regional considerations, the industry pricing environment in the third quarter remained favorable on the back of higher raw material prices and tighter supply conditions. The global composite benzene to caprolactam spread increased nearly 40% in the quarter on a year-over-year basis and increased a more modest 17% sequentially. As a reminder, China represents over 40% of global caprolactam capacity and demand, so pricing movements there will heavily influence the global composite and overall dynamics. We’re seeing prices fluctuate near levels that we would associate with marginal producer costs compared to the…

Thanks Erin. I’m now on Slide 9, and we’d like to spend a little more time discussing what we’re seeing and expecting for the fourth quarter. From a commercial perspective, we anticipate a similar supply and demand environment to what we saw in the third quarter across our major product lines. In particular, we’re continuing to monitor the impacts of government imposed environmental constraints in China as we enter the peak winter heating season in the region. Operationally, we expect continued strong results. Our turnaround and mechanical integrity programs, which have been maturing for years now, are really key components to our operational performance. As we’ve discussed, we expect our fourth quarter planned turnaround impact to pre-tax income to be approximately $20 million. From a sequential perspective, this compares to a minimal impact from turnaround in the third quarter, so a key consideration to our expected results in the fourth quarter. As Erin reported and I’m happy to report that we are executing the turnaround on time, on budget, and we are near completion. There are some other considerations as it relates to cash flow generation in the fourth quarter. Capex is tracking to approximately $90 million for the full year, as we previously discussed, or roughly $25 million for the fourth quarter. Of course, there will be some timing and working capital considerations around our planned turnaround. We’ll likely see some level of cash outflow as a result of raw material spend and maintenance expenses related to the turnaround. In addition, there may also be some timing differences between the deployment of our committed capital investments versus the actual cash outflow. We also expect to see some level of pre-buy advances in the fourth quarter for ammonium sulfate as is common in that business, which results in some timing…

Thanks Mike. I’m now on Slide 11 for a brief summary. In just over a year of being a public company, we’ve demonstrated the strength and value proposition of our operational leverage. We have a focused strategy that we’re executing against built on rigorous commitment to operational excellence, continuous enhancement of research and development capabilities, and an emphasis on longer term growth oriented investments. We’ve made a number of strides in 2017, creating a foundation that will position the company for strong operational and financial performance for years to come. Our leading cost position is serving us well through the dynamics of our end markets. We’re highly focused on safe operational output and we’re driving continued strong working capital performance and improved cash flow generation. In 2018, our priorities are centered on continuing to drive safe and stable operations, enhancing our long term growth capabilities, and making smart investments in the business to drive higher returns. The momentum in 2017 will serve us well and we remain confident in our ability to drive value creation over the long term. With that, Adam, let’s move to Q&A.

Thanks Erin. Rachel, can you please open the line for Q&A?

[Operator instructions] The first question comes from Chris Moore with CJS. Please go ahead.

Hey, good morning guys. Great quarter.

Thanks Chris.

Thank you.

So maybe just start with--obviously volume was up 5% year-over-year. From a Q2 to Q3 perspective, can you talk about the volume change?

Sure. When you think about sort of where we sit by product line, we certainly saw strong demand, robust kind of across all three segments. Volume is going to be up relative in intermediates. When you think about the sales in Q3 as it relates to the Harvey situation, and we certainly tried to help out everyone there when there were challenges - about 60% of the phenol acetone capacity was offline as a result of that, so that’s sort of one deeper detail there for you. Seasonally on ammonium sulfate, Q3 is a weaker quarter relative just to the seasonality - it’s a little bit stronger on the export side than it is on the domestic. Then on caprolactam and nylon, certainly that continued as well, just with robust demand in North America and certainly in the export markets as well. So with the ability to continue to drive the output out of the facilities, the sales team is doing a great job in placing all of that material.

Got you, thank you. Looking at Q4, obviously it’s on a year-over-year basis hard to do because of all the outages in Q416, so I’m just trying to look at it on a sequential basis. Obviously you’ve got the turnaround in Q4. The ammonium sulfate that’s sold in Q4 tends to be a little bit lower gross margin because it’s sold to South America than sold previously - is that true?

Well, I think what we’d--you know, similar to our commentary and what we’d want you to walk away with is right now we’re seeing really the quarter on a sequential basis kind of stable throughout the product lines. In ammonium sulfate particularly, we’re entering into seasonally stronger quarters - you’ve got fall application and then ahead as you enter into the spring season, so overall from a top line perspective, I think you can kind of look at Q3 and then carry that forward again with certainly some of the commentary around nylon operating globally in and around the marginal producer economics. Sulfate is continuing to move into seasonally stronger quarters, so as we think about those dynamics and continued sort of robustness in the intermediate space, and then just with a consideration for the turnaround.

Got it. Back to something Mike said, so in terms of 2018 turnaround, normally it’s kind of 40/60 Q2/Q4. Next year, it’s going to be 80% Q2, is that what was said?

That’s correct.

Okay. Got it. All right, I’ll jump back in queue and go from there. Thanks guys.

Thanks Chris.

Again if you have a question, please press star then one. At this time, we will pause for just a moment to gather any additional questions. The next question comes from Chip Saye with AWH Capital. Please go ahead.

Thanks for taking my questions. I have a question as it relates to the annualized plant production. You guys have done a good job of increasing production year-over-year and then, as you’ve shown on Slide 8, over the 2012 to 2015 average. The bottlenecking projects that you have planned potentially for next year, what could we add in terms of capacity to the three plants with those projects?

Chip, it’s a great question and one that’s it’s probably just a little bit early to where we’re ready to disclose that piece of information. I think as we’ve shared in the past, relative to sort of the underlying operational excellence capabilities, sort of that lower single digit and continuing to, I would say, decrease the variability, shift the mean inside our plants can yield sort of in that low single digit percent year-on-year. Then when we think about the debottlenecking, that really would be ’18 into ’19, and so that additional capacity would be a ’19 consideration. But as we come to the end of finalizing those projects, we’ll be back to disclose more on those terms, but consider it as really as a ’19 consideration.

Okay, I appreciate that. Secondly on the caprolactam and nylons markets, you have the advantaged cost position and the new plants that are coming on in China, I just want to flesh that out a little more with you. New plants are coming on but then they’re taking off or reducing capacity at existing plants - can you just talk about that?

Sure. So when you look at the overall build-out of capacity in China over the last several years, there’s been, I would say, across the spectrum of types of operations. There are independent producers with standalone caprolactam facilities, there are others that have put up the capacity to integrate forward into polymerization and downstream into textiles - you know, yarn and fiber, so there’s varying degrees of how that capacity has come on-stream. What has been and we have been observing over the last year has been the consideration around the environmental considerations as China has become, not just in our value chain but others, looking to address air quality and water quality, so when you think about where that emphasis is, typically in the north part of China about a third of the caprolactam capacity sits in that arena, in that region, and so with that tightened consideration some of those plants are being asked to shut down, to shutter. There is environmental permitting checks and investments to address those, but I think as we think forward, while new capacity could come online and in many cases the ones we’re seeing are those that will be integrated versus standalone, so they’ll have a natural play going forward, and so as you look at it, there is dynamics to play out relative to those standalone caprolactam plants that will be not integrated in the future, and then a real question as to who will make the necessary investments to meet the forward permitting requirements

Okay, so the focus seems to be integrated plants going forward and maybe some of the non-integrated standalone plants that were older plants may shutter, or require investment to continue to operate because of the permitting costs. Fair enough?

That’s fair enough; and again, we haven’t seen any official announcements, I would say, of official closures, if you will, but certainly they’re operating at much lower rates, which is allowing now the dynamic to, as we said, sort of fluctuate in and around the marginal producer economics versus being depressed, which is what we saw in ’16. So I think you have dynamics we’re watching, and we’ll continue to share more as we see things evolve.

Okay. Lastly, can you give an update on some of the newer nylons that you’re working on, the higher margin products? I think you’ve talked about that in the past, and kind of creating products for your customers. Can you just touch on that?

Sure. We’re continuing to put an emphasis behind our copolymer capabilities, as we’ve shared in the past. We brought on the capability to produce a high nylon 6 content, triple-6 copolymer. We’re seeing success in it being used in engineering plastics with a number of conversions today. Now again, these are small part components, but a number of active programs for automotive parts or even additional consumer oriented parts where plastics can be made. Enduring plastics, it provides the nice benefit of smooth and better surface finish. In glass-filled components, it reduces warpage so you get better dimensional stability of those parts as they are in use. Our sales teams and technical marketing teams continue to be out to promote that, recognizing that these have longer term qualification processes, so we’re out working with customers. They need to qualify it with their end customers and OEMs, but we continue to fill that out as well as work on customer programs and the use for packaging films. Packaging films is a smaller, I would say, demand segment for nylon but one growing on a fast basis vis-à-vis sort of the lightweighting of packaging, particularly in food. There, you get higher transparency, higher strength, and again those customer programs continue on but those qualification programs are--can vary in length from six to nine months, and sometimes even further than that, so.

All right, well listen - thanks for the detail, and a good quarter.

Great, thanks Chip. Appreciate the call.

Again if you have a question, please press star then one. At this time, we will pause for just a moment to gather any additional questions. This concludes our question and answer session. I would like to turn the conference back over to Erin Kane for any closing remarks.

Thank you. We’re pleased to share with you the results of another robust quarter that when combined with the first half results highlights our strong execution, leveraging our operating model and our ability to perform in dynamic market conditions. We’ve made a number of strides as a public company this past year and have set a solid foundation for future performance. Building upon this foundational year, we’ll continue to focus on safe and stable operations, strong working capital results and delivering improved cash flow all while enhancing our long-term growth capabilities. We’re building great momentum and we look forward to sharing more with you next quarter. Thank you again for your time and interest this morning.

The conference has now concluded. Thank you for attending today’s presentation. You may now disconnect.